Clinical Trial Update: A Study of ASP8273 in Subjects With Non-small Cell Lung Cancer (NSCLC) Harboring Epidermal Growth Factor Receptor (EGFR) Mutations [Phase 1]

View source ↗

Summary

Phase 1 study of ASP8273 in EGFR-mutated non-small cell lung cancer has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• ASP8273

Snippet

Sponsor: Astellas Pharma Global Development, Inc. | Conditions: Non-small Cell Lung Cancer (NSCLC), Epidermal Growth Factor Receptor (EGFR) Mutations | Phase 1 | Status: TERMINATED